Evidence map›Paper›PMID 39836849›Full record

ArticleBiomedica : revista del Instituto Nacional de Salud2024

Standardization of the use of opsonized zymosan as stimulus in the 1,2,3-dihydrorhodamine technique for the assessment of neutrophil respiratory burst

Uriel Pérez-Blanco, Jenniffer Yissel Girón, Guillermo Juárez-Vega, María Jiménez, Carlos Sánchez, Ricardo Rioja, Sara Espinosa-Padilla, Lizbeth Blancas-Galicia

Abstract readEnglish Abstract
In one paragraph

Article in Biomedica : revista del Instituto Nacional de Salud, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Uriel Pérez-BlancoLaboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Ciudad de México, México.ORCID 0009-0000-2156-2166
Jenniffer Yissel GirónRed de Apoyo a la Investigación, Coordinación de la Investigación Científica, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Universidad Nacional Autónoma de México, Ciudad de México, México.ORCID 0000-0001-7027-9615
Guillermo Juárez-VegaRed de Apoyo a la Investigación, Coordinación de la Investigación Científica, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Universidad Nacional Autónoma de México, Ciudad de México, México.ORCID 0000-0002-0633-0567
María JiménezLaboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Ciudad de México, México.ORCID 0009-0004-1437-5214
Carlos SánchezLaboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Ciudad de México, México.ORCID 0009-0007-6263-442X
Ricardo RiojaLaboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Ciudad de México, México.ORCID 0000-0003-1894-2525
Sara Espinosa-PadillaLaboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Ciudad de México, México.ORCID 0000-0003-4859-3151
Lizbeth Blancas-GaliciaLaboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Ciudad de México, México.ORCID 0000-0002-3861-8864

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chronic granulomatous disease is a defect in phagocytosis due to deficiency of gp91phox, p22phox, p47phox, p40phox, and p67phox (classic form of the disease). Recently, EROS and p40phox deficiency were described as responsible for the non-classical form of the disease. The 1,2,3-dihydrorhodamine oxidation technique, with phorbol-12-myristate-13-acetate as a stimulus, is performed to diagnose the classic chronic granulomatous disease. However, oxidation mediated by EROS and p40phox requires stimuli such as zymosan, Escherichia coli, or Staphylococcus aureus. Objective: To optimize the 1,2,3-dihydrorhodamine technique using zymosan to assess neutrophil respiratory burst and detect the non-classical chronic granulomatous disease. Materials and method: Blood was obtained from five healthy subjects after the signature of the informed consent. The 1,2,3-dihydrorhodamine technique was performed with phorbol-12-myristate-13-acetate as control and different quantities of opsonized zymosan (150, 100, 50, 20, and 10 μg). We obtained through flow cytometry the mean fluorescence intensity of rhodamine 1,2,3 oxidated in the neutrophil population and calculated the oxidation index. The Kolmogorov-Smirnov test, ANOVA, and Tukey’s post-hoc analysis were used. We considered a p value ≤ 0.05 as statistically significant. Results: The phorbol-12-myristate-13-acetate increased the rhodamine 1,2,3 mean fluorescence intensity in healthy subjects. Among the different zymosan conditions tested, we selected 50 μg as the optimal and reproducible amount in all controls according to the statistical analysis and cytometric findings. Conclusions: We present the optimization of the 1,2,3-dihydrorhodamine technique using zymosan. We propose its implementation in clinical diagnostic laboratories to expand the diagnosis of chronic granulomatous disease.

Indexed as

Granulomatous Disease, ChronicNeutrophilsRespiratory BurstRhodaminesZymosanAdultFemaleFlow CytometryHumansMalePhagocytosisTetradecanoylphorbol AcetateRhodaminesTetradecanoylphorbol AcetateZymosanchronicgranulomatous diseaseNADPH oxidaserhodamine 1,2,3zymosan

Identifiers

PMID39836849
PMCPMC12014214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.